

John A Snowden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/870430/publications.pdf>

Version: 2024-02-01

251
papers

10,017
citations

34105

52
h-index

43889

91
g-index

264
all docs

264
docs citations

264
times ranked

10219
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England: a UK NEQAS LI survey. <i>Journal of Clinical Pathology</i> , 2023, 76, 618-623.	2.0	1
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. <i>Haematologica</i> , 2022, 107, 1045-1053.	3.5	87
3	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	2.4	4
4	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	1.2	5
5	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	2.4	11
6	The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346.	2.4	2
7	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752.	2.4	45
8	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation—study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	2.4	4
9	Benchmarking survival outcomes: A funnel plot for survival data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1171-1183.	1.5	5
10	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	2.5	3
11	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	2.4	2
12	Comparison of fludarabine+melphalan and fludarabine+treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	2.4	6
13	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
14	The impact of COVID-19 on related donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey. <i>British Journal of Haematology</i> , 2022, 198, .	2.5	2
15	Non-Responsive and Refractory Coeliac Disease: Experience from the NHS England National Centre. <i>Nutrients</i> , 2022, 14, 2776.	4.1	10
16	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. <i>Haematologica</i> , 2021, 106, 375-383.	3.5	57
17	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	2.4	8
18	Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 673-678.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annual Review of Medicine, 2021, 72, 215-228.	12.2	44
20	Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. Journal of Neurology, 2021, 268, 265-275.	3.6	27
21	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	8.4	18
22	Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with "aggressive" multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1198-1204.	3.0	22
23	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	2.4	221
24	Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit. British Journal of Haematology, 2021, 192, e151-e154.	2.5	3
25	The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP. Frontiers in Neurology, 2021, 12, 645263.	2.4	11
26	New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplantation, 2021, 56, 1509-1517.	2.4	14
27	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 2021, 56, 1493-1508.	2.4	27
28	Autologous Hematopoietic Stem Cell Transplantation for Behçet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Frontiers in Immunology, 2021, 12, 638709.	4.8	6
29	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone Marrow Transplantation, 2021, 56, 2820-2825.	2.4	7
30	The promise and challenges of cell therapy for psoriasis*. British Journal of Dermatology, 2021, 185, 887-898.	1.5	13
31	Long-term survivors following autologous haematopoietic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. Vaccine, 2021, 39, 4778-4783.	3.8	6
32	Autologous HSCT Conditioning Regimens for Autoimmune Diseases. , 2021, , 204-212.		0
33	Visions for a JACIE Quality Management System 4.0. Bone Marrow Transplantation, 2021, 56, 2876-2881.	2.4	3
34	Quality, Accreditation, and Regulation in Hematopoietic Stem Cell Transplantation. , 2021, , 103-109.		0
35	Late Toxicity and Supportive Care of Patients Undergoing Hematopoietic Cell Transplantation for Autoimmune Diseases. , 2021, , 252-263.		0
36	Early Toxicity and Supportive Care of Hsct for Autoimmune Diseases. , 2021, , 241-251.		0

#	ARTICLE	IF	CITATIONS
37	Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study. <i>Physiotherapy</i> , 2021, 113, 88-99.	0.4	7
38	The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact. <i>British Journal of Haematology</i> , 2021, 192, 467-473.	2.5	20
39	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	2.4	2
40	Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. <i>Blood Advances</i> , 2021, 5, 4500-4503.	5.2	6
41	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. <i>Frontiers in Oncology</i> , 2021, 11, 722436.	2.8	6
42	Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. <i>Blood Advances</i> , 2021, , .	5.2	0
43	OFR-9...An RCT of autologous stem-cell transplantation in treatment refractory Crohn's disease (low-intensity therapy evaluation): ASTIClite. , 2021, , .		0
44	Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM). <i>Bone Marrow Transplantation</i> , 2021, 56, 730-732.	2.4	2
45	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 441-451.	2.4	22
46	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	2.4	128
47	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
48	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 131-142.	0.9	14
49	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
50	Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. <i>Bone Marrow Transplantation</i> , 2020, 55, 1512-1515.	2.4	12
51	Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1473-1475.	2.4	9
52	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
53	P149—Haematopoietic stem cell transplantation in systemic sclerosis: Sheffield Teaching Hospitals' experience. <i>Rheumatology</i> , 2020, 59, .	1.9	1
54	Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-centre international study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 938-949.	1.6	15

#	ARTICLE	IF	CITATIONS
55	Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102404.	2.0	14
56	Gender gaps in transplantation. <i>British Journal of Haematology</i> , 2020, 190, e123-e125.	2.5	0
57	Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1299-1313.	2.8	7
58	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Neurology</i> , 2020, 11, 556141.	2.4	8
59	A Case of Multiple Sclerosis-“Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. <i>Frontiers in Immunology</i> , 2020, 11, 668.	4.8	8
60	Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 2109-2113.	2.4	8
61	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	2.4	163
62	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	2.4	147
63	Non-Responsive Coeliac Disease: A Comprehensive Review from the NHS England National Centre for Refractory Coeliac Disease. <i>Nutrients</i> , 2020, 12, 216.	4.1	52
64	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. <i>Bone Marrow Transplantation</i> , 2020, 55, 1840-1843.	2.4	3
65	Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. <i>Acta Haematologica Polonica</i> , 2020, 51, 73-80.	0.3	6
66	Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). <i>Frontiers in Immunology</i> , 2020, 11, 81.	4.8	19
67	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
68	Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT. <i>Blood</i> , 2020, 136, 11-13.	1.4	0
69	Intention to Treat Analysis of Real-World Outcomes Following Tisagenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. <i>Blood</i> , 2020, 136, 18-19.	1.4	2
70	Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. <i>Blood</i> , 2020, 136, 3-4.	1.4	1
71	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	4.1	9
72	The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 981-985.	3.0	17

#	ARTICLE	IF	CITATIONS
73	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. <i>EClinicalMedicine</i> , 2019, 15, 33-41.	7.1	8
74	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	4.8	48
75	Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002960.	8.4	18
76	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140
77	Low-dose methotrexate: potential clinical impact on haematological and constitutional symptoms in myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2019, 187, e69-e72.	2.5	1
78	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-942.	2.4	25
79	Autologous stem cell transplantation in refractory Crohn's disease: low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	2.0	17
80	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
81	Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 127-135.	2.3	21
82	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1617-1628.	1.6	24
83	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
84	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from <sc>BSBMT</sc>/<sc>UKMF</sc> Myeloma X) Tj ETQg 0 0 rgBT /Overl	2.5	14
85	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	2.4	129
86	PF173 RESULTS FROM UKALL60+, A UK PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA. <i>HemaSphere</i> , 2019, 3, 38-39.	2.7	0
87	Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 394-401.	1.3	10
88	Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 201-208.	1.5	15
89	Vitamin D: is it important in haematopoietic stem cell transplantation? A review. <i>Bone Marrow Transplantation</i> , 2019, 54, 810-820.	2.4	28
90	Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 165.	7.4	208

#	ARTICLE	IF	CITATIONS
91	Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. <i>British Journal of Haematology</i> , 2019, 185, 89-92.	2.5	28
92	Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 783-796.	2.8	22
93	Impact of T cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. <i>American Journal of Hematology</i> , 2019, 94, 80-86.	4.1	16
94	JACIE Accreditation of HSCT Programs. , 2019, , 35-40.		11
95	Autoimmune Disease. , 2019, , 677-683.		4
96	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. <i>Blood</i> , 2019, 134, 2746-2746.	1.4	1
97	Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2019, 134, 4483-4483.	1.4	0
98	BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. <i>Blood</i> , 2019, 134, 3313-3313.	1.4	1
99	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 3338-3338.	1.4	0
100	Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4574-4574.	1.4	1
101	Title is missing!. , 2019, 16, e1002960.		0
102	Title is missing!. , 2019, 16, e1002960.		0
103	Title is missing!. , 2019, 16, e1002960.		0
104	Title is missing!. , 2019, 16, e1002960.		0
105	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	1.3	43
106	Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study. <i>BMJ Open</i> , 2018, 8, e021333.	1.9	12
107	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
108	UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. <i>Journal of Clinical Apheresis</i> , 2018, 33, 46-59.	1.3	42

#	ARTICLE	IF	CITATIONS
109	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	1.3	29
110	Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. <i>Journal of Autoimmunity</i> , 2018, 92, 35-46.	6.5	51
111	Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. <i>Clinical Medicine</i> , 2018, 18, 329-334.	1.9	34
112	Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD4+ Low Intensity Therapy Evaluation Study Investigators. <i>Frontiers in Immunology</i> , 2018, 9, 646.	4.8	25
113	Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. <i>Blood</i> , 2018, 132, 255-255.	1.4	4
114	Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3425-3425.	1.4	3
115	Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP). <i>Blood</i> , 2018, 132, 3431-3431.	1.4	0
116	Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study. <i>Blood</i> , 2018, 132, 251-251.	1.4	0
117	Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. <i>Blood</i> , 2018, 132, 3213-3213.	1.4	1
118	Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT. <i>Blood</i> , 2018, 132, 2070-2070.	1.4	0
119	Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. <i>British Journal of Haematology</i> , 2017, 176, 888-907.	2.5	44
120	Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. <i>Bone Marrow Transplantation</i> , 2017, 52, 775-777.	2.4	16
121	Conditioning regimens for autologous haematopoietic stem cell transplantation - can natural killer cell therapy help?. <i>British Journal of Haematology</i> , 2017, 177, 341-342.	2.5	1
122	Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). <i>Journal of Clinical Pathology</i> , 2017, 70, 461-468.	2.0	12
123	Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes. <i>Bone Marrow Transplantation</i> , 2017, 52, 889-894.	2.4	14
124	Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. <i>Bone Marrow Transplantation</i> , 2017, 52, 1495-1503.	2.4	88
125	Low-dose methotrexate in myeloproliferative neoplasm models. <i>Haematologica</i> , 2017, 102, e336-e339.	3.5	9
126	JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. <i>Bone Marrow Transplantation</i> , 2017, 52, 1367-1371.	2.4	61

#	ARTICLE	IF	CITATIONS
127	Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. <i>Leukemia</i> , 2017, 31, 1752-1759.	7.2	23
128	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2017, 52, 811-817.	2.4	310
129	Observational study of the development and evaluation of a fertility preservation patient decision aid for teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research protocol. <i>BMJ Open</i> , 2017, 7, e013219.	1.9	32
130	Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. <i>Bone Marrow Transplantation</i> , 2017, 52, 1674-1677.	2.4	22
131	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e23.	0.4	1
132	Lineage-specific chimerism monitoring after allogeneic haematopoietic stem cell transplantation: do we really know what we are measuring?. <i>British Journal of Haematology</i> , 2017, 176, 139-141.	2.5	2
133	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182.	2.4	61
134	Autologous hematopoietic cell transplantation in multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 77-86.	3.1	11
135	Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. <i>Brain</i> , 2017, 140, 953-966.	7.6	53
136	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	5.2	151
137	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	1.4	0
138	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
139	High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for "late effects" screening and preventive strategies. <i>Hematology</i> , 2016, 21, 272-279.	1.5	6
140	Rebooting autoimmunity with autologous HSCT. <i>Blood</i> , 2016, 127, 8-10.	1.4	17
141	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e340-e351.	4.6	120
142	Guidelines for the diagnosis and management of adult aplastic anaemia. <i>British Journal of Haematology</i> , 2016, 172, 187-207.	2.5	539
143	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. <i>British Journal of Haematology</i> , 2016, 172, 360-370.	2.5	79
144	Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. <i>British Journal of Haematology</i> , 2016, 172, 478-481.	2.5	1

#	ARTICLE	IF	CITATIONS
145	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	12.8	94
146	Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice. <i>Current Research in Translational Medicine</i> , 2016, 64, 71-82.	1.8	32
147	Does ex vi vo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?. <i>Bone Marrow Transplantation</i> , 2016, 51, 501-505.	2.4	39
148	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1009-1016.	2.0	8
149	Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 385-390.	2.0	151
150	Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. <i>Clinical Endocrinology</i> , 2016, 84, 296-304.	2.4	5
151	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Blood</i> , 2016, 128, 2293-2293.	1.4	2
152	Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. <i>Blood</i> , 2016, 128, 4585-4585.	1.4	1
153	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	1.4	1
154	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	1.4	1
155	Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2016, 128, 2266-2266.	1.4	1
156	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2015, 2, 2101-2109.	6.1	36
157	Time to redefine Myeloma. <i>British Journal of Haematology</i> , 2015, 171, 1-10.	2.5	18
158	The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 365-371.	6.4	460
159	Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). <i>Bone Marrow Transplantation</i> , 2015, 50, 216-220.	2.4	38
160	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. <i>Bone Marrow Transplantation</i> , 2015, 50, 173-180.	2.4	71
161	Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. <i>Supportive Care in Cancer</i> , 2015, 23, 671-678.	2.2	36
162	Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. <i>Lancet</i> , The, 2015, 385, S98.	13.7	26

#	ARTICLE	IF	CITATIONS
163	AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANT IN MS: SHEFFIELD COHORT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.116-e4.	1.9	0
164	Improved tumor response and survival outcomes with post-transplant bortezomib (Btz) consolidation versus observation (Obs) alone in patients with newly diagnosed multiple myeloma (MM): Results from a randomized, open-label, multicenter, parallel-group phase 2 study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e129-e130.	0.4	0
165	Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party. <i>Blood</i> , 2015, 126, 1210-1210.	1.4	4
166	Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. <i>Blood</i> , 2015, 126, 1985-1985.	1.4	1
167	A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. <i>Blood</i> , 2015, 126, 394-394.	1.4	4
168	NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. <i>PLoS ONE</i> , 2015, 10, e0119546.	2.5	36
169	Methotrexate Is a JAK/STAT Pathway Inhibitor. <i>PLoS ONE</i> , 2015, 10, e0130078.	2.5	123
170	Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. <i>Blood</i> , 2015, 126, 1981-1981.	1.4	20
171	Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. <i>Blood</i> , 2015, 126, 3180-3180.	1.4	0
172	Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 907-912.	2.4	39
173	Position statement on the use of bendamustine in myeloma. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 20-28.	1.3	10
174	Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 42-48.	2.4	65
175	Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 871-877.	0.5	25
176	Updates to the guidelines for the diagnosis and management of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 131-133.	2.5	20
177	Myeloma bone disease: pathogenesis, current treatments and future targets. <i>British Medical Bulletin</i> , 2014, 111, 117-138.	6.9	61
178	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI T1070). <i>Journal of Clinical Oncology</i> , 2015, 33, 874-885.	10.7	139
179	Holistic needs assessment in advanced, intensively treated multiple myeloma patients. <i>Supportive Care in Cancer</i> , 2014, 22, 2615-2620.	2.2	24
180	Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling. <i>Blood</i> , 2014, 124, 4577-4577.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?. Blood, 2014, 124, 2517-2517.	1.4	0
182	Living With Advanced But Stable Multiple Myeloma: A Study of the Symptom Burden and Cumulative Effects of Disease and Intensive (Hematopoietic Stem Cell Transplant-Based) Treatment on Health-Related Quality of Life. Journal of Pain and Symptom Management, 2013, 46, 671-680.	1.2	86
183	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 666-669.	2.0	17
184	Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis. Journal of Neurology, 2013, 260, 914-916.	3.6	11
185	Improving safety in autologous HSCT for systemic sclerosis. Lancet, The, 2013, 381, 1081-1083.	13.7	4
186	The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 2013, 122, 3378-3378.	1.4	1
187	A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 2013, 122, 765-765.	1.4	1
188	Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. Blood, 2013, 122, 1884-1884.	1.4	0
189	Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP). Blood, 2013, 122, 4640-4640.	1.4	0
190	Unrelated Cord Blood Transplantation (UCBT) In Adults In The UK: Evolution, Experience and Outcomes. A Retrospective Analysis On Behalf Of The British Society of Blood and Marrow Transplantation (BSBMT) and Eurocord. Blood, 2013, 122, 3394-3394.	1.4	1
191	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	2.4	256
192	Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 369-371.	0.5	7
193	A study of pain, peripheral neuropathy and psychosocial late effects in multiple myeloma patients. BMJ Supportive and Palliative Care, 2012, 2, A3.2-A3.	1.6	1
194	Haematopoietic stem cell transplantation (<sc>HSCT</sc>) in severe autoimmune diseases: analysis of <sc>UK</sc> outcomes from the British Society of Blood and Marrow Transplantation (<sc>BSBMT</sc>) data registry 1997â€“2009. British Journal of Haematology, 2012, 157, 742-746.	2.5	36
195	Comparative Effectiveness of Lenalidomide Plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. Blood, 2012, 120, 4076-4076.	1.4	1
196	Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood, 2011, 118, 1693-1698.	1.4	140
197	Reâ€“transplantation after bortezomibâ€“based therapy. British Journal of Haematology, 2011, 153, 666-668.	2.5	8
198	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	2.5	252

#	ARTICLE	IF	CITATIONS
199	Guidelines for supportive care in multiple myeloma 2011. British Journal of Haematology, 2011, 154, 76-103.	2.5	176
200	S135 A retrospective multi-centre study of the effects of allogeneic haematopoietic stem cell transplantation on pulmonary function. Thorax, 2011, 66, A62-A62.	5.6	1
201	Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response. Blood, 2011, 118, 324-324.	1.4	1
202	National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). Blood, 2011, 118, 52-52.	1.4	2
203	Quality of life, self-esteem, fatigue, and sexual function in young men after cancer. Cancer, 2010, 116, 1592-1601.	4.1	60
204	T1747 Autologous Stem Cell Transplantation for Severe, Treatment-Refractory Crohn's Disease: the UK Experience to Date. Gastroenterology, 2010, 138, S-570.	1.3	0
205	Risks of Immune System Treatments. Science, 2010, 328, 825-826.	12.6	24
206	Increased fat mass may be protective of bone mass in young male cancer survivors. Bone, 2010, 47, S189-S190.	2.9	0
207	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. Blood, 2010, 116, 2322-2322.	1.4	0
208	Clinical stem cell therapies for severe autoimmune diseases. Transfusion Medicine, 2009, 19, 223-234.	1.1	6
209	IgA lambda myeloma presenting concurrently in identical twins with subsequent transformation to an aggressive phase™ in one. International Journal of Laboratory Hematology, 2008, 17, 95-96.	0.2	3
210	Stem cell transplantation in rheumatoid arthritis. Autoimmunity, 2008, 41, 625-631.	2.6	19
211	Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoietic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival. Blood, 2008, 112, 2391-2391.	1.4	0
212	Haemopoietic stem cell transplantation™ an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology, 2007, 12, 179-191.	1.5	27
213	Prevalence and Consequences of Androgen Deficiency in Young Male Cancer Survivors in a Controlled Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3476-3482.	3.6	92
214	The Uhthoff phenomenon: a potential post transplant complication in advanced progressive multiple sclerosis. Bone Marrow Transplantation, 2007, 40, 1003-1004.	2.4	7
215	Follow-up care for young adult survivors of cancer: lessons from pediatrics. Journal of Cancer Survivorship, 2007, 1, 75-86.	2.9	23
216	Factors Predicting Long Term Survival after Reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.. Blood, 2007, 110, 326-326.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2007, 110, 1055-1055.	1.4	11
218	Livedo reticularis associated with hereditary protein C deficiency and recurrent thromboembolism. <i>British Journal of Dermatology</i> , 2006, 132, 283-285.	1.5	8
219	Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. <i>Arthritis and Rheumatism</i> , 2006, 54, 3750-3760.	6.7	110
220	Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. <i>British Journal of Haematology</i> , 2005, 128, 432-459.	2.5	77
221	Autologous hematopoietic stem cell transplantation for autoimmune diseases. <i>Bone Marrow Transplantation</i> , 2005, 35, 869-879.	2.4	190
222	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , 2005, 7, R80.	2.0	75
223	Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.. <i>Blood</i> , 2005, 106, 641-641.	1.4	10
224	Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. <i>Journal of Rheumatology</i> , 2004, 31, 482-8.	2.0	125
225	Highly Selected Autologous Stem Cell Transplantation in Severe Rheumatoid Arthritis with Studies of Peripheral Blood Lymphocyte (Pbl) Reconstitution, Synovial Response and Thymic Function. <i>Clinical Science</i> , 2002, 103, 33P-33P.	0.0	0
226	High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 837-839.	6.7	44
227	A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2301-2309.	6.7	153
228	Autologous stem cell transplantation for rapidly progressive Jo-1 positive polymyositis with long-term follow-up. <i>British Journal of Haematology</i> , 2001, 113, 840-841.	2.5	25
229	Collection of hematopoietic stem cells from patients with autoimmune diseases. <i>Bone Marrow Transplantation</i> , 2001, 28, 1-12.	2.4	124
230	Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. <i>Bone Marrow Transplantation</i> , 2000, 26, 309-313.	2.4	68
231	Special Lectures on the Pathogenesis and the Pathogenesis-based Treatment of Rheumatoid Arthritis. Haemopoetic stem cell transplantation in autoimmune diseases, with special reference to rheumatoid arthritis.. <i>Japanese Journal of Clinical Immunology</i> , 2000, 23, 257-260.	0.0	0
232	Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. <i>Bone Marrow Transplantation</i> , 1999, 24, 729-734.	2.4	149
233	A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2286-2292.	6.7	85
234	A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. <i>Bone Marrow Transplantation</i> , 1998, 22, 1035-1041.	2.4	91

#	ARTICLE	IF	CITATIONS
235	Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis and Rheumatism, 1998, 41, 453-459.	6.7	123
236	Angiotropic lymphoma: report of a case with histiocytic features.. Journal of Clinical Pathology, 1997, 50, 67-70.	2.0	30
237	Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 1997, 19, 1247-1250.	2.4	109
238	Allogeneic bone marrow transplantation from a donor with severe active rheumatoid arthritis not resulting in adoptive transfer of disease to recipient. Bone Marrow Transplantation, 1997, 20, 71-73.	2.4	35
239	Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. British Journal of Dermatology, 1997, 137, 130-132.	1.5	45
240	HAEMOPOIETIC STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES. British Journal of Haematology, 1997, 99, 9-22.	2.5	87
241	Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis and Rheumatism, 1997, 40, 1712-1715.	6.7	81
242	Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. British Journal of Dermatology, 1997, 137, 130-132.	1.5	68
243	Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. British Journal of Dermatology, 1997, 137, 130-2.	1.5	21
244	Autologous blood stem cell transplantation for autoimmune diseases. Lancet, The, 1996, 348, 1112-1113.	13.7	31
245	The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography. International Journal of Laboratory Hematology, 1996, 18, 277-279.	0.2	2
246	Reversal of diabetes associated with escape of myeloma: evidence for inappropriate IGF-II secretion. British Journal of Haematology, 1994, 87, 202-204.	2.5	8
247	Dilatation of the colon complicating acute self-limited colitis. The Quarterly Journal of Medicine, 1994, 87, 55-62.	1.0	6
248	HLA and ICAM-1 expression in alopecia areata<i>in vivo</i>and<i>in vitro</i>: the role of cytokines. British Journal of Dermatology, 1993, 129, 250-256.	1.5	53
249	Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Endocrine Abstracts, 0, , .	0.0	0
250	Is stem cell transplantation safe and effective in multiple sclerosis?. BMJ, The, 0, , e061514.	6.0	3
251	Association of genetic variants with patient reported quality of life and pain experience in patients in 0, , .	2.4	1